TrialBMC infectious diseases2024

Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.

Tao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.